National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

HARDBACK
price:$52.95
add to cart

Rights & Permissions

topleft topright

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)
Institute of Medicine (IOM)

Citation Manager

. "Appendix 25: Streptococcus, Group B." Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press, 2000.

Please select a format:

BibTeX EndNote RefMan


Page
307
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Vaccines for the 21st Century: A Tool for Decisionmaking

Table 25–2 Disease Scenarios for Group B Streptococcus Infection in Infants and Adults

 

% of Cases

Committee HUI Values

Duration (years)

INFANTS

 

Bacteremia—NICU

36.0%

0.24

0.027 (10 days)

Bacteremia—Non-NICU

36.0%

0.24

0.027 (10 days)

Meningitis

6.4%

0.27

0.047 (17 days)

Meningitis with impairment

1.1%

 

acute care (50% NICU; 50% Level 2)

 

0.27

0.047 (17 days)

permanent impairment—normal lifespan

 

0.53

26.804 (discounted quality adjusted life expectancy at birth)

Meningitis with early death

0.5%

 

acute care

 

0.27

0.047 (17 days)

permanent impairment

 

0.53

10.000 (10 years)

death by age 10

 

0.00

25.690 (discounted quality adjusted life expectancy at age 10)

LATE ONSET DISEASE—20% of infant cases

Bacteremia

14.0%

0.69

0.027 (10 days)

Meningitis

4.8%

0.27

0.047 (17 days)

Meningitis with impairment

0.8%

 

acute care

 

0.27

0.047 (17 days)

permanent impairment—normal lifespan

 

0.53

26.804 (discounted quality adjusted life expectancy at birth)

Meningitis with early death

0.4%

 

acute care

 

0.27

0.047 (17 days)

permanent impairment

 

0.53

10.000 (10 years)

death by age 10

 

0.00

25.690 (discounted quality adjusted life expectancy at age 10)

ADULTS

 

Maternal Infection

100%

 

inpatient

 

0.68

0.0192 (7 days)

outpatient treatment

 

0.0137 (5 days)

NONPREGNANT ADULTS

 

Invasive disease

100.0%

 

soft tissue, bone infection; bacteremia; urosepsis; pneumonia

 

0.66

0.052 (19 days)

Page
307
Front Matter (R1-R12)
Executive Summary (1-10)
Introduction (11-16)
Progress in Vaccine Development (17-38)
Considerations of Candidate Vaccines (39-52)
Overview of Analytic Approach and Results (53-92)
Review of the Analytical Model (93-108)
Ethical Considerations and Caveats (109-122)
Observations (123-132)
References (133-142)
Appendix 1: Borrelia burgdorferi (143-148)
Appendix 2: Chlamydia (149-158)
Appendix 3: Coccidioides Immitis (159-164)
Appendix 4: Cytomegalovirus (165-172)
Appendix 5: Enterotoxigenic E. coli (173-176)
Appendix 6: Epstein-Barr Virus (177-180)
Appendix 7: Helicobacter pylori (181-188)
Appendix 8: Hepatitis C (189-194)
Appendix 9: Herpes Simplex Virus (195-206)
Appendix 10: Histoplasma capsulatum (207-212)
Appendix 11: Human Paillomavirus (213-222)
Appendix 12: Influenza A and B (223-232)
Appendix 13: Insulin-Dependent Diabetes Mellitus (233-238)
Appendix 14: Melanoma (239-244)
Appendix 15: Multiple Sclerosis (245-250)
Appendix 16: Mycobacterium tuberculosis (251-256)
Appendix 17: Neisseria gonnorrhea (257-266)
Appendix 18: Neisseria meningitidis (267-272)
Appendix 19: Parainfluenza Virus (273-278)
Appendix 20: Respiratory Syncytial Virus (279-284)
Appendix 21: Rheumatoid Arthritis (285-290)
Appendix 22: Rotavirus (291-294)
Appendix 23: Shigella (295-298)
Appendix 24: Streptococcus, Group A (299-304)
Appendix 25: Streptococcus, Group B (305-312)
Appendix 26: Streptococcus pneumoniae (313-322)
Appendix 27: Information on accessing Electronic Spreadsheets (323-324)
Appendix 28: Summary of Workshops (325-434)
Appendix 29: Questions Posed to Outside Experts and List of Responders (435-442)
Index (443-460)